As of March 31, 2025, Immunovant’s (IMVT) cash and cash equivalents totaled approximately $714 million, providing runway for announced indications through GD readout expected in 2027.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- IMVT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Gran Tierra, Immunovant, AIM, Cracker Barrel, JB Hunt: Insider Moves Unveiled!
- Immunovant’s Strategic Leadership and Portfolio Expansion Justify Buy Rating
- Immunovant downgraded to Neutral from Buy at UBS
- Immunovant’s Strategic Developments and Growth Potential Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue